Triveni Bio Initiates Phase 1 Trial of Dual-Target Bispecific Antibody TRIV-573 for Atopic Dermatitis
Key Insights
Triveni Bio (search) has dosed the first healthy volunteers with TRIV-573, a bispecific antibody targeting both KLK5 (search)/7 and IL-13 (search) pathways in a Phase 1 clinical trial.
The dual-mechanism approach combines barrier repair through KLK5 (search)/7 inhibition with anti-inflammatory IL-13 (search) blockade to address multiple aspects of atopic dermatitis (search) pathology.
The company plans to advance TRIV-573 into a Phase 2 proof-of-concept study in moderate-to-severe atopic dermatitis (search) patients in the second half of 2026.
Triveni Bio (search) has achieved a significant milestone in atopic dermatitis (search) drug development by dosing the first healthy volunteers with TRIV-573, a next-generation bispecific antibody designed to simultaneously target kallikreins 5 (search) and 7 (KLK5 (search)/7) and interleukin-13 (search) (IL-13 (search)). The Phase 1 clinical trial initiation marks the advancement of what the company describes as a first-in-class therapeutic approach for patients with atopic dermatitis.
Novel Dual-Targeting Mechanism
TRIV-573 represents a departure from traditional single-target approaches by combining two distinct mechanisms of action. The bispecific antibody leverages Triveni's novel barrier repair mechanism through KLK5 (search)/7 inhibition alongside an established anti-inflammatory mechanism via IL-13 (search) blockade. This orthogonal approach aims to break what the company refers to as the "Th2 efficacy ceiling" and address the considerable unmet need in atopic dermatitis (search) treatment.
"TRIV-573 builds on compelling preclinical evidence that KLK5 (search)/7 inhibition addresses all three pillars of AD pathology: barrier, inflammation, and itch," said Bhaskar Srivastava, M.D., Ph.D., Chief Medical Officer of Triveni Bio (search). "We have demonstrated preclinical additivity when combining the KLK5/7 mechanism with Th2 targeting, positioning TRIV-573 as a novel combination approach for moderate-to-severe AD with a single therapeutic designed for infrequent, patient-friendly dosing."
Addressing Multiple Pathways in Atopic Dermatitis
The dual targeting strategy reflects an evolution in atopic dermatitis (search) treatment approaches, moving beyond addressing inflammation alone to tackle the underlying dysfunction of the skin barrier. TRIV-573's design capitalizes on the promise of combination approaches by integrating barrier repair with anti-inflammatory mechanisms in a single half-life extended bispecific antibody.
The company has demonstrated preclinical additivity when combining the KLK5 (search)/7 mechanism with Th2 targeting, suggesting potential for enhanced efficacy compared to single-target approaches. This positioning aims to address the three key pillars of atopic dermatitis (search) pathology: barrier dysfunction, inflammation, and itch.
Rapid Clinical Development Timeline
The initiation of the Phase 1 study represents rapid progress in Triveni's clinical portfolio expansion. The company plans to advance TRIV-573 into a Phase 2 patient proof-of-concept trial in moderate-to-severe atopic dermatitis (search) during the second half of 2026.
"Advancing TRIV-573 into the clinic less than one year after TRIV-509 is a testament to our team's execution," said Vishal Patel, Ph.D., Chief Executive Officer. "We are thrilled to progress this unique therapy as we work to break the existing efficacy ceiling for patients with AD and other I&I disorders."
Complementing Lead Program Development
TRIV-573 development runs parallel to Triveni's lead program TRIV-509, a half-life extended monoclonal antibody targeting KLK5 (search)/7 for moderate-to-severe atopic dermatitis (search) treatment. TRIV-509 is currently the subject of an ongoing Phase 2 proof-of-concept trial with data expected by the end of 2026.
Through its mechanism of protease inhibition, TRIV-509 has demonstrated the ability to directly impact each key pillar of atopic dermatitis (search): barrier dysfunction, inflammation, and itch. The parallel development of both programs positions Triveni to potentially offer multiple therapeutic options targeting the KLK5 (search)/7 pathway.
Strategic Focus on Genetics-Informed Drug Development
Triveni Bio (search)'s approach reflects a genetics-informed, precision medicine strategy aimed at establishing proof-of-concept early in the drug development process. The company leverages deep insights into genetic and mechanistic biology to develop antibody-based therapies for immunological and inflammatory disorders.
The advancement of TRIV-573 into clinical testing represents the company's commitment to addressing unmet medical needs in atopic dermatitis (search) through innovative therapeutic approaches that target multiple disease mechanisms simultaneously.